Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
Real-life Assessment of Aripiprazole Long-acting Injection (Abilify Maintena) Combined With Brexpiprazole (Rexulti) in Schizophrenia: a Naturalistic Non-interventional Prospective Follow-up Study
The University of Hong Kong
10 participants
Feb 1, 2022
OBSERVATIONAL
Conditions
Summary
MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorder prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in a real-life clinical setting.
Eligibility
Inclusion Criteria5
- Age: 18- 65 years old at the time of enrollment
- Able to read and communicate in English and/or Chinese
- Able to give informed consent
- Has been diagnosed to have Schizophrenia (DSM-5 or ICD-10 F20 \[except F20.81\], Schizotypal (Personality) Disorder (DSM-5 or ICD-10 F21), or Schizoaffective Disorder (DSM-5 or ICD-10 F25), (Persistent) Delusional Disorder (DSM-5 or ICD-10 F22), Schizophreniform Disorder (DSM-5 or ICD-10 F20.81), Brief Psychotic Disorder (DSM-5) or Acute and Transient Psychotic Disorder (ICD-10 F23)
- Is receiving the combination with Abilify Maintena and brexpiprazole as treatment ≤8 weeks at the time of recruitment
Exclusion Criteria4
- Age \<18 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Interventions
subject already receiving the combination of Abilify Maintena and Rexulti
subject already receiving the combination of Abilify Maintena and Rexulti
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05169268